Deferred income

12 Months Ended

Dec. 31, 2025

Deferred income

Deferred income

29. Deferred income

The movement in the non-current and current deferred income is detailed in the table below.


		Gilead collaboration agreement for filgotinib			Gilead collaboration agreement for drug discovery platform⁽¹⁾			Other deferred income			Total

		(Euro, in thousands)

On January 1, 2024		€	26,268		€	1,299,163		€	2,032		€	1,327,463
Of which current portion:			25,054			230,070			1,146			256,270

Significant financing component ⁽²⁾			(227)									(227)

Revenue recognition of upfront			(21,952)			(230,182)						(252,134)
Revenue recognition of milestones			(4,089)									(4,089)

Other movements									339			339

On December 31, 2024		€	—		€	1,068,981		€	2,371		€	1,071,352
Of which current portion:			—			230,105			2,371			232,476

Revenue recognition of upfront						(1,068,967)						(1,068,967)

Other movements						(14)			(2,339)			(2,353)

On December 31, 2025		€	—		€	—		€	32		€	32
Of which current portion:			—			—			32			32

(1)	The upfront received and the outstanding balance comprised the issuance liabilities for the warrants and the upfront payment allocated to the drug discovery platform.

(2)	With regard to the additional consideration received for the extended cost sharing for filgotinib, we assumed the existence of a significant financing component reflecting the time value of money on the estimated recognition period

We refer to note 2 for a detail of the allocation of the transaction price of our OLCA with Gilead and to note 5 and note 7 for a description of our revenue recognition.